Top Biomedical Science
@imedverse
Biomedical Science that Inspires. #medicine #medtwitter #meded #Science #Research #Technology #News
ID:1886086740
20-09-2013 10:38:31
12,7K Tweets
78,2K Followers
4,7K Following
Follow People
Terrific session at #ESMO2023 on early TNBC led by four giants of TNBC research.
It is clear that we need to integrate biomarkers already, to finally select patients for proper tp escalation and de-escalation.
Congrats Aleix Prat #PrecisionOncology Rebecca Dent V.Guarneri P. Schmid
#ESMO2023
4️⃣PROpel: PFS benefit. Genomic Profiling: high concordance with DDR.
5️⃣ ct DNA HIGH CONCORDANCE.
6️⃣ VISION: we need a lot to do. Personalized Therapy.
7️⃣ PSMA intensity could be predictive.
silke gillessen Advanced Prostate Cancer Consensus Conference OncoAlert
Grateful for the opportunity to discuss important data at #ESMO2023 on the rapidly growing role of immunotherapy in gastrointestinal cancer. Understanding tumor biology is key. Chiara Cremolini Filippo Pietrantonio Lizzy Smyth Myriam Chalabi Sam Klempner Sara Lonardi Pamela Kunz, MD
STEAP1 as a potential #biomarker for #Immunotherapy in prostate cancer #pcsm
#Xaluritamig ph1 trial safe and tolerable.
CRS more frequent AE ⚠
ESMO - Eur. Oncology
OncoAlert #ESMO2023
🧐PFS and OS by TCGA classifiers was quite intriguing
🌟POLE does well no matter what
🌟MMRd improved survival with IO (as expected)
🌟p53m improved survival with IO (not what I would expect!!!)
#EndometrialCancer #gyncsm #ESMO2023 #ImmunoOnc
'You can't get complete responses with KRAS inhibitors.' Quote from: every KRAS researcher
Revolution Medicines: 'Hold my beer'
Complete response!
#ESMO23 #ESMO2023 KRASKickers #CancerResearch
Syed A. Ahmad Anirban Maitra
#ESMO2023
4️⃣PROpel: PFS benefit. Genomic Profiling: high concordance with DDR.
5️⃣ ct DNA HIGH CONCORDANCE.
6️⃣ VISION: we need a lot to do. Personalized Therapy.
7️⃣ PSMA intensity could be predictive.
silke gillessen Advanced Prostate Cancer Consensus Conference OncoAlert
🔥Breaking News at #ESMO2023 !🔥 EV302 is changing the game, unbelievable data (HR=0.45!!!) for metastatic urothelial cancer patients, really an evolution #EV302 . Terrific presentation by Tom Powles. 🙌🔬🎗️ UroToday.com OncoAlert ESMO - Eur. Oncology
💐The BOUQUET trial is a novel biomarker-directed platform trial in rare #OvarianCancer - so brilliant and allows seamless enrollment of #RareCancers #ESMO2023 #gyncsm
Congratulations Nicolas Girard for this new standard of care for our EGFRex20ins NSCLC patients, a great step forward. Need to manage the skin tox with amivantamab ESMO - Eur. Oncology #ESMO2023
👏Camrelizumab (anti-PD1) + famitinib (TKI) has improved response rate (42.9%) vs camrelizumab alone (22%) or chemotherapy (14.3%) in recurrent #CervicalCancer - extremely intriguing data that will need larger study
#ESMO2023 #gyncsm #ImmunoOnc
🆕 insights from the STAMPEDE trial presented #ESMO2023 :
5️⃣-year incidence of upper urinary tract obstruction significantly ⬇️ with prostate RT in all men with mHSPC❗️
#ProstateCancer Chris Parker Nick James ESMO - Eur. Oncology OncoAlert ESTRO ASTRO